Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Incorporated in 2002, Brooks Laboratories Limited is engaged in the manufacturing and marketing of pharmaceuticals nationally as well as at the international level. The company has its own manufacturing facility located at Baddi, Himachal Pradesh.
A Research and Development driven Pharmaceutical manufacturing company proffering a variety of solutions to customers.
Brooks Laboratories is a Pharmaceutical Contract Research and Manufacturing Services entity. They offer a wide range of products specifically catering to the critical care segment in Parental Section. The offerings include Beta Lactam, Ampoules and Liquid vials, General Dry powder Injectables, Dry Syrups and Tablets.
Products range includes:
With a motivated team of highly qualified professionals, the company is working to stabilize new molecules in niche segments, in order to offer stable latest products to the end customers.
| Issue Open | August 7, 2023 - August 22, 2023 |
| Security Name | Brooks Laboratories Limited |
| Issue Size (Shares) | 1,543,926 |
| Issue Size (Amount) | ₹11.58 Crores |
| Issue Price | ₹75 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
| Terms of Payment | Full amount of Rs. 75 for rights equity shares has to be paid on application. |
| Entitlement | 1 Rights Equity Share(s) for every 16 fully paid-up Equity Shares held on Record Date |
| Last Date to buy shares | July 27, 2023 |
| Record Date | July 28, 2023 |
| Credit of Rights Entitlements | August 3, 2023 |
| Bid/Offer Opens On | August 7, 2023 |
| Renunciation of Rights Entitlements | August 17, 2023 |
| Bid/Offer Closes On | August 22, 2023 |
| Deemed Date of Allotment | August 29, 2023 |
| Credit Date | August 30, 2023 |
| Listing Date | September 1, 2023 |
| Period Ended | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 195.91 | 109.60 |
| Revenue | 91.99 | 63.41 |
| Profit After Tax | -18.31 | -31.05 |
| Net Worth | ||
| Reserves and Surplus | ||
| Total Borrowing |
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
3 3.0 Rating:  Vote Here ... |
Brooks Laboratories Limited
Vill.Kishanpura,
Nalagarh Road,
Baddi - 174101
Phone: +91-1795 - 236939
Email: investors@brookslabs.net
Website: https://www.brookslabs.net/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: brooks.rights2023@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
The Brooks Laboratories Rights Issue 2023 opens on August 7, 2023, and closes on August 22, 2023.
Brooks Laboratories Rights Issue 2023 Schedule
| Last Date for credit of Rights Entitlements | August 3, 2023 |
| Last Date for renunciation of Rights Entitlements | August 17, 2023 |
| Issue Opening Date | August 7, 2023 |
| Issue Closing Date | August 22, 2023 |
| Date of Allotment (on or about) | August 29, 2023 |
| Date of Credit (on or about) | August 30, 2023 |
| Date of Listing (on or about) | September 1, 2023 |
Brooks Laboratories Rights Issue 2023 price is set at ₹75 per share per equity share.
The eligible shareholders are being offered 1 Rights Equity Share(s) for every 16 fully paid-up Equity Shares held on Record Date (July 28, 2023).
The record date for the Brooks Laboratories Rights Issue 2023 is July 28, 2023.
The issue size of Brooks Laboratories Rights Issue 2023 is of 1,543,926 equity shares at ₹75 per share aggregating upto ₹11.58 Crores.
The Letter of Offer for Brooks Laboratories Rights Issue 2023 can be download here.
You can apply for Brooks Laboratories Rights Issue 2023 in two ways:
Steps to apply for Brooks Laboratories Rights Issue 2023 using Net Banking (ASBA)
Note: Your bank may not offer this facility to certain rights issues. In that case, you may have to choose the option below.
Steps to apply for Brooks Laboratories Rights Issue 2023 using Registrar's website (R-WAP)
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
